Shareholders approve 2025 Employee Stock Purchase Plan; directors elected

enGene Therapeutics Inc.

Shareholders approved the 2025 ESPP reserving 2,000,000 common shares for issuance.
Directors Gerald Brunk and Dr. Richard Glickman were elected with 30.5M and 26.3M for votes respectively.
ESPP effective June 10, 2025, allows eligible employees to purchase shares via payroll deductions.
Auditor appointment ratified with 38,101,229 votes in favor.
ESPP intended to qualify under Code Section 423; 74.6% of outstanding shares voted at the meeting.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.